Flossbach Von Storch SE Grows Position in Ralliant Corporation $RAL

Flossbach Von Storch SE boosted its stake in shares of Ralliant Corporation (NYSE:RAL) by 1.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,152,866 shares of the company’s stock after purchasing an additional 67,963 shares during the period. Flossbach Von Storch SE owned approximately 3.68% of Ralliant worth $181,605,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the stock. GAMMA Investing LLC acquired a new stake in shares of Ralliant during the 2nd quarter worth $56,000. Public Employees Retirement System of Ohio acquired a new stake in Ralliant during the second quarter worth about $1,799,000. State of Alaska Department of Revenue purchased a new position in shares of Ralliant in the 2nd quarter worth about $2,788,000. V Square Quantitative Management LLC acquired a new position in shares of Ralliant in the 2nd quarter valued at about $131,000. Finally, Truist Financial Corp acquired a new position in shares of Ralliant in the 2nd quarter valued at about $1,409,000.

Ralliant Price Performance

Shares of RAL stock opened at $52.95 on Thursday. The firm has a fifty day simple moving average of $51.19 and a 200-day simple moving average of $46.60. The company has a market capitalization of $5.97 billion and a PE ratio of 41.69. Ralliant Corporation has a twelve month low of $40.70 and a twelve month high of $55.25. The company has a current ratio of 1.49, a quick ratio of 1.03 and a debt-to-equity ratio of 0.39.

Ralliant (NYSE:RAL) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.02. The firm had revenue of $529.10 million during the quarter, compared to analyst estimates of $519.14 million. Ralliant has set its Q4 2025 guidance at 0.620-0.680 EPS.

Analysts Set New Price Targets

RAL has been the topic of several research reports. Royal Bank Of Canada raised their price target on shares of Ralliant from $45.00 to $52.00 and gave the company a “sector perform” rating in a report on Friday, November 7th. Oppenheimer increased their price objective on shares of Ralliant from $55.00 to $60.00 and gave the stock an “outperform” rating in a research report on Monday, December 15th. Weiss Ratings reissued a “hold (c)” rating on shares of Ralliant in a research note on Monday, December 29th. Citigroup raised shares of Ralliant from a “neutral” rating to a “buy” rating and upped their price target for the stock from $53.00 to $61.00 in a research report on Monday, December 8th. Finally, Truist Financial initiated coverage on Ralliant in a research report on Friday, December 12th. They issued a “buy” rating and a $62.00 price objective on the stock. Six investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $58.00.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.